There are two ways to be in the consumer health business.
The first is to sell a supplement, a subscription, or a lifestyle product. Fast onboarding, viral acquisition, high churn accepted as a cost of doing business. Exit inside seven years. This is what most of the industry has been for a decade. It produced some real companies and a large volume of noise.
The second is to build a healthcare company. Compliance infrastructure that costs more upfront and returns durability. A physician network with actual economics. Customer relationships measured in years. Institutional capital that expects boring quarterly numbers for long stretches at a time.
The category is finishing its migration from the first to the second. Most of the industry does not yet know it.
I. The Forcing Function
Four regulatory frameworks in consumer health are being rewritten simultaneously in 2026. DEA telemedicine rules. The FDA’s peptide reclassification. GLP-1 shortage lists closing, unwinding a compounded-semaglutide economy that at its peak generated a meaningful share of direct-to-consumer telehealth revenue. The pharmacy compounding regime governing the back end.
Anyone would be decade-defining. Four in eighteen months is what happens when a category grows too fast for its regulatory infrastructure and the infrastructure catches up.
The consequence is not that DTC health is being shut down. It is being professionalized. Operators who built compliance depth during the loose years are about to be rewarded. Operators who did not are about to be exposed.
II. What Compliance Depth Actually Costs
Compliance depth is not a legal budget. It is an organizational shape.
The multi-state physician licensing pattern that took three years to build. Pharmacy relationships negotiated on quality terms rather than price. A medical review layer that makes patient files auditable above the current regulator’s bar. Documentation discipline that survives a fifty-state audit without a fire drill.
The wellness-brand model does not need any of this. The healthcare-company model needs all of it, pays for it up front, and looks slower for the first several years as a result. A regulatory reset is what separates the two. Four at once is what accelerates it.
III. The Physician Network as the Underrated Asset
In the twelve-year DTC health cycle ending in 2026, the metric everyone tracked was customer acquisition cost. It was the wrong metric. The metric that matters on the other side is physician network economics.
The consumer health company at scale is a physician network in a marketing wrapper. The wrapper is what the customer sees. The network is what determines the margin, the compliance posture, the ability to expand into adjacent conditions, and the durability of the whole business.
The companies that emerge as institutional players are the ones that treated the physician network as the central asset for the entire prior cycle. Hims & Hers has one. Ro has one. A handful of others have quietly built competitive networks. The rest will find that a physician network cannot be assembled quickly.
The consumer health company at scale is a physician network in a marketing wrapper.
IV. The Long-Term Customer
The customer relationship in the wellness-brand model is transactional. Buy, churn, reacquire at cost, churn again. Lifetime value is a function of retention math on a stock model.
The customer relationship in the healthcare-company model is a care relationship. The primary product is not a subscription — it is continuity. The patient stays because switching is expensive, because their history is with the provider, because the relationship compounds the way a private-banking relationship compounds. Lifetime value is measured in years, and the ceiling is materially higher.
This is the axis on which the category will be repriced. The businesses that got the customer to sign up will lose to the businesses that kept the patient for a decade.
V. Institutional Capital’s Arrival
Institutional capital is arriving in consumer health for the first time. Not the venture funds. The pension funds, the sovereigns, the multi-strategy asset managers, the family offices, the credit funds that write nine-figure checks with ten-year holds.
It wants a specific kind of company. Durability, not growth. Compliance depth, not marketing velocity. Recurring revenue that survives regulatory scrutiny. Management teams that have built through cycles. Companies that look, at the level of financial reporting, like healthcare companies rather than direct marketing companies.
Institutional capital does not fund the first model. It funds the second. And it is at the door.
VI. The Long-Duration Health Company
The mature consumer health company in 2031 will look more like a healthcare provider than a direct-to-consumer brand. A physician network measured in thousands. Multi-state operations audited above the regulator’s bar. Patient relationships compounding across years.
Boring from the outside. One of the most valuable company types in the country.
I write this from inside the work. VeriMed Tech Holdings is building the durable version. It is a slower company than the marketing model would produce. That is not an accident; it is the point.
Consumer health used to be a marketing category. It is becoming a healthcare category. The companies that understood this before the reset will still exist in 2031. Most of the others will not.